Please Wait.....
Report
MEA Gene Therapy Market - Industry Trends and Forecast to 2030
Market Report I 2023-03-01 I 130 Pages I Data Bridge Market Research
Middle East and Africa gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Middle East and Africa Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (South Africa and Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the gene therapy market are:
- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy
Market Players:
The key market players for Middle East and Africa gene therapy market are listed below:
- Amgen, Inc.
- AnGes, Inc
- Biogen
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Janssen Pharmaceuticals, Inc.
- Novartis AG
TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 MARKET END USER COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTER FIVE ANALYSIS 41
5 UPDATE ON GERMLINE GENE THERAPY 42
5.1 GERMLINE GENE THERAPY 42
6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO 43
6.1 DRIVERS 45
6.1.1 NOVEL APPROACHES TO GENE THERAPY 45
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 45
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 46
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 47
6.2 RESTRAINTS 47
6.2.1 HIGH COST OF GENE THERAPY 47
6.2.2 ETHICAL AND SAFETY CONCERNS 48
6.2.3 COMPLEXITY OF GENE THERAPY 48
6.3 OPPORTUNITIES 49
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 49
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 49
6.4 CHALLENGES 50
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 50
6.4.2 LONG-TERM SAFETY AND EFFICACY 50
7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE 51
7.1 OVERVIEW 52
7.2 VIRAL VECTOR 55
7.2.1 ADENOVIRUS 56
7.2.2 RETROVIRUS 56
7.2.3 LENTIVIRUS 56
7.2.4 ADENO-ASSOCIATED VIRUS 56
7.2.5 VACCINIA VIRUS 56
7.2.6 HERPES SIMPLEX VIRUS 56
7.2.7 OTHERS 56
7.3 NON-VIRAL VECTOR 56
7.3.1 LIPOFECTION 57
7.3.2 INJECTION OF NAKED DNA 57
8 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD 58
8.1 OVERVIEW 59
8.2 EX-VIVO 62
8.3 IN-VIVO 62
9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION 64
9.1 OVERVIEW 65
9.2 ONCOLOGICAL DISORDERS 68
9.3 CARDIOVASCULAR DISEASES 68
9.4 INFECTIOUS DISEASES 69
9.5 RARE DISEASES 70
9.6 NUEROLOGICAL DISORDERS 71
9.7 OTHER DISEASES 72
10 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 CANCER INSTITUTES 77
10.3 HOSPITALS 77
10.4 RESEARCH INSTITUTES 78
10.5 OTHERS 79
11 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION 80
11.1 MIDDLE EAST AND AFRICA 81
11.1.1 SOUTH AFRICA 87
11.1.2 REST OF MIDDLE EAST AND AFRICA 89
12 MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE 90
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 90
13 COMPANY PROFILES 91
13.1 BIOGEN 91
13.1.1 COMPANY SNAPSHOT 91
13.1.2 REVENUE ANALYSIS 91
13.1.3 COMPANY SHARE ANALYSIS 92
13.1.4 SWOT ANALYSIS 92
13.1.5 PRODUCT PORTFOLIO 93
13.1.6 RECENT DEVELOPMENT 93
13.2 KITE PHARMA 94
13.2.1 COMPANY SNAPSHOT 94
13.2.2 REVENUE ANALYSIS 94
13.2.3 COMPANY SHARE ANALYSIS 95
13.2.4 SWOT ANALYSIS 95
13.2.5 PRODUCT PORTFOLIO 96
13.2.6 RECENT DEVELOPMENT 96
13.3 NOVARTIS AG 97
13.3.1 COMPANY SNAPSHOT 97
13.3.2 REVENUE ANALYSIS 97
13.3.3 COMPANY SHARE ANALYSIS 98
13.3.4 SWOT ANALYSIS 98
13.3.5 PRODUCT PORTFOLIO 99
13.3.6 RECENT DEVELOPMENTS 99
13.4 BRISTOL-MYERS SQUIBB COMPANY. 100
13.4.1 COMPANY SNAPSHOT 100
13.4.2 REVENUE ANALYSIS 100
13.4.3 COMPANY SHARE ANALYSIS 101
13.4.4 SWOT ANALYSIS 101
13.4.5 PRODUCT PORTFOLIO 102
13.4.6 RECENT DEVELOPMENT 102
13.5 OXFORD BIOMEDICA 103
13.5.1 COMPANY SNAPSHOT 103
13.5.2 REVENUE ANALYSIS 103
13.5.3 COMPANY SHARE ANALYSIS 104
13.5.4 SWOT ANALYSIS 104
13.5.5 PRODUCT PORTFOLIO 105
13.5.6 RECENT DEVELOPMENTS 105
13.6 AGC BIOLOGICS 106
13.6.1 COMPANY SNAPSHOT 106
13.6.2 PRODUCT PORTFOLIO 106
13.6.3 RECENT DEVELOPMENT 106
13.7 ANGES, INC 107
13.7.1 COMPANY SNAPSHOT 107
13.7.2 REVENUE ANALYSIS 107
13.7.3 PRODUCT PORTFOLIO 108
13.7.4 RECENT DEVELOPMENT 108
13.8 AMGEN INC. 109
13.8.1 COMPANY SNAPSHOT 109
13.8.2 REVENUE ANALYSIS 109
13.8.3 PRODUCT PORTFOLIO 110
13.8.4 RECENT DEVELOPMENT 110
13.9 BLUEBIRD BIO, INC. 111
13.9.1 COMPANY SNAPSHOT 111
13.9.2 PRODUCT PORTFOLIO 111
13.9.3 RECENT DEVELOPMENT 111
13.10 CHIESI FARMACEUTICI S.P.A 112
13.10.1 COMPANY SNAPSHOT 112
13.10.2 REVENUE ANALYSIS 112
13.10.3 PRODUCT PORTFOLIO 113
13.10.4 RECENT DEVELOPMENT 113
13.11 DENDREON PHARMACEUTICALS LLC 114
13.11.1 COMPANY SNAPSHOT 114
13.11.2 PRODUCT PORTFOLIO 114
13.11.3 RECENT DEVELOPMENT 114
13.12 ENZYVANT THERAPEUTICS GMBH 115
13.12.1 COMPANY SNAPSHOT 115
13.12.2 RODUCT PORTFOLIO 115
13.12.3 RECENT DEVELOPMENT 115
13.13 FERRING B.V. 116
13.13.1 COMPANY SNAPSHOT 116
13.13.2 PRODUCT PORTFOLIO 116
13.13.3 RECENT DEVELOPMENT 116
13.14 JANSSEN PHARMACEUTICALS, INC. 117
13.14.1 COMPANY SNAPSHOT 117
13.14.2 PRODUCT PORTFOLIO 117
13.14.3 RECENT DEVELOPMENT 117
13.15 MALLINCKRODT. 118
13.15.1 COMPANY SNAPSHOT 118
13.15.2 REVENUE ANALYSIS 118
13.15.3 PRODUCT PORTFOLIO 119
13.15.4 RECENT DEVELOPMENT 119
13.16 ORCHARD THERAPEUTICS PLC. 120
13.16.1 COMPANY SNAPSHOT 120
13.16.2 REVENUE ANALYSIS 120
13.16.3 PRODUCT PORTFOLIO 121
13.16.4 RECENT DEVELOPMENT 121
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 122
13.17.1 COMPANY SNAPSHOT 122
13.17.2 PRODUCT PORTFOLIO 122
13.17.3 RECENT DEVELOPMENT 122
13.18 SIBONO 123
13.18.1 COMPANY SNAPSHOT 123
13.18.2 PRODUCT PORTFOLIO 123
13.18.3 RECENT DEVELOPMENT 123
13.19 SPARK THERAPEUTICS, INC. 124
13.19.1 COMPANY SNAPSHOT 124
13.19.2 PRODUCT PORTFOLIO 124
13.19.3 RECENT DEVELOPMENT 124
13.20 UNIQURE NV. 125
13.20.1 COMPANY SNAPSHOT 125
13.20.2 REVENUE ANALYSIS 125
13.20.3 PRODUCT PORTFOLIO 126
13.20.4 RECENT DEVELOPMENT 126
14 QUESTIONNAIRE 127
15 RELATED REPORTS 130
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security